Compare Lockheed Martin Corporation (LMT) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lockheed Martin Corporation vs ResMed Inc. — how do they compare? Lockheed Martin Corporation trades at $509.59 (market cap $117.22B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: Lockheed Martin Corporation is far larger — about 3.7× ResMed Inc.'s market cap, and Lockheed Martin Corporation pays the higher dividend (2.72%). Which is the better fit depends on your goals — on Pluang, investors hold Lockheed Martin Corporation for 86 Days and ResMed Inc. for 51 Days on average.
| LMT | RMD | |
|---|---|---|
Market Cap | $117.22B | $31.89B |
Volume | 1,101,121 | 618,314 |
Sector | Industrials | Health |
52-Week High | $676.70 | $277.88 |
52-Week Low | $439.19 | $182.82 |
Typical Hold Time | 86 Days | 51 Days |
Enterprise Value | $133.96B | $31.24B |
Dividend Yield | 2.72% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lockheed Martin (LMT) trades at $509.59, up 2.08% over the past day, with a bearish technical signal but strong analyst consensus. The company reported mixed quarterly earnings, missing in Q4 2025 and Q1 2026 but beating in Q2 2026, while revenue and cash flow trends show growth. Recent news highlights innovation in AI and autonomous systems, dividend increases, and ongoing defense contracts, supporting a positive long-term outlook despite near-term volatility.
LMT presents a compelling investment case with a consensus price target of $635.33, implying significant upside, backed by robust cash flows and a dominant defense market position. Risks include reliance on government spending, fixed-price contract volatility, and rising debt levels, but the stock's current valuation and dividend track record offer a margin of safety for patient investors.
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
